A Phase 2 interventional study of GWP42003-P and Placebo in Schizophrenia, sponsored by Jazz Pharmaceuticals. Terminated at 39 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-06-15.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cannabidiol in Schizophrenia — none open to participants now, none under way, none of them phase 3. Cannabidiol · Schizophrenia.
Among the 10 studies testing cannabidiol in Schizophrenia, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 7 in phase 2, and was the 9th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 10 studies testing cannabidiol in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 42 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 7 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 3 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing cannabidiol in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnosis and Psychiatric History
Treatment History
Past and Current Medical History
Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GWP42003-P 300 milligrams (mg) per day
Drug: GWP42003-P
Matching placebo
Drug: Placebo
GWP42003-P 1000 mg per day
Drug: GWP42003-P
oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
Least Square Mean Change From Baseline in the Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) Score
The PANSS-T is a medical scale used for measuring symptom severity of participants with schizophrenia or related psychotic disorder. It is a 30-item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. A PANSS-T score is derived from the sum of the 30 items and the total score ranges from 30 to 210, where higher scores represent worse outcome. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
Time frame: Baseline up to Week 12
Least Square Mean Change From Baseline in the PANSS Positive Subscale (PANSS-P) Score
The PANSS 'P' Scale was calculated as the sum of the items prefixed with an P, 7 items in total, i.e. delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
Time frame: Baseline up to Week 12
Least Square Mean Change From Baseline in the PANSS Negative Subscale (PANSS-N) Score
The PANSS 'N' Scale will be calculated as the sum of the items prefixed with an N, 7 items in total, i.e. blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
Time frame: Baseline up to Week 12
Least Square Mean Change From Baseline in the PANSS General Subscale (PANSS-G) Score
The PANSS 'G' Scale will be calculated as the sum of the items prefixed with a G, 16 items in total, i.e. somatic concerns, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
Time frame: Baseline up to Week 12
Least Square Mean Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score
The CGI-S is a 7-point scale used to rate the severity of participants' illness at the time of assessment. Considering total clinical experience, a participant will be assessed on severity of mental illness at the time of rating 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = among the most extremely ill participants. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
Time frame: Baseline up to Week 12
Number of Participants With Minimally or Better Clinical Global Impression of Improvement (CGI-I) Score at Week 12
The CGI-I is a 7-point scale used to rate the improvement of participants' condition at the time of assessment. Compared to the patient's condition at baseline, the participants' condition was rated as 1 = very much improved since initiation of treatment; 2 = much improved; 3 = minimally improved; 4 = no change from baseline; 5 = minimally worse; 6 = much worse; 7 = very much worse since the initiation of treatment. Higher scores indicate a worse outcome. The number of participants with minimally or better improvements (score of 3 or better) are being reported.
Time frame: Week 12
Mean Change From Baseline in Body Weight
Time frame: Baseline up to Week 12
Mean Change From Baseline in Body Mass Index (BMI)
Time frame: Baseline up to Week 12
Mean Change From Baseline in Waist Circumference
Time frame: Baseline up to Week 12
Mean Change From Baseline in Blood Pressure
Time frame: Baseline up to Week 12
Mean Change From Baseline in Heart Rate
Time frame: Baseline up to Week 12
Mean Change From Baseline in Respiratory Rate
Time frame: Baseline up to Week 12
Mean Change From Baseline in Temperature
Time frame: Baseline up to Week 12
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Test Results
Time frame: Day 85
Number of Participants With Defined Flagged Electrocardiogram (ECG) Parameter Values
Time frame: Day 85
Number of Participants With Suicidal Ideation or Behavior Based on The Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a short questionnaire that is used to assess suicidal ideation (5 questions) and behavior (5 questions) since last patient visit. The questionnaire is completed by participants answering yes or no to each question.
Time frame: Baseline (screening) up to Day 85
A total of 95 participants who met all inclusion and no exclusion criteria were enrolled in the study and were randomized to the Placebo Run-in Period. Eighteen participants failed the Placebo Run-in Period. A total of 77 participants were randomized to 1 of 2 GWP42003-P doses or placebo treatment at a 2:2:1:1 ratio at 33 clinic centers.
| Milestone | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Started | 0 | 0 | 95 |
| Completed | 0 | 0 | 77 |
| Not completed | 0 | 0 | 18 |
| Withdrew: Placebo run-in failures | 0 | 0 | 18 |
| Milestone | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Started | 27 | 24 | 26 |
| Completed | 23 | 19 | 19 |
| Not completed | 4 | 5 | 7 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal of parent/legal representative consent | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 |
| Withdrew: Participant non-compliance | 1 | 1 | 2 |
| Withdrew: Other | 0 | 1 | 3 |
The PANSS-T is a medical scale used for measuring symptom severity of participants with schizophrenia or related psychotic disorder. It is a 30-item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. A PANSS-T score is derived from the sum of the 30 items and the total score ranges from 30 to 210, where higher scores represent worse outcome. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
| units on a scale | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Least Square Mean Change From Baseline in the Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) Score | -10.49 ± 1.64 | -10.69 ± 1.75 | -8.74 ± 1.78 |
The PANSS 'P' Scale was calculated as the sum of the items prefixed with an P, 7 items in total, i.e. delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
| units on a scale | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Least Square Mean Change From Baseline in the PANSS Positive Subscale (PANSS-P) Score | -3.16 ± 0.59 | -3.75 ± 0.63 | -2.53 ± 0.62 |
The PANSS 'N' Scale will be calculated as the sum of the items prefixed with an N, 7 items in total, i.e. blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
| units on a scale | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Least Square Mean Change From Baseline in the PANSS Negative Subscale (PANSS-N) Score | -2.64 ± 0.53 | -1.57 ± 0.56 | -2.33 ± 0.58 |
The PANSS 'G' Scale will be calculated as the sum of the items prefixed with a G, 16 items in total, i.e. somatic concerns, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
| units on a scale | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Least Square Mean Change From Baseline in the PANSS General Subscale (PANSS-G) Score | -4.78 ± 1.03 | -4.91 ± 1.10 | -3.68 ± 1.09 |
The CGI-S is a 7-point scale used to rate the severity of participants' illness at the time of assessment. Considering total clinical experience, a participant will be assessed on severity of mental illness at the time of rating 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = among the most extremely ill participants. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.
| units on a scale | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Least Square Mean Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score | -0.47 ± 0.11 | -0.50 ± 0.12 | -0.45 ± 0.12 |
The CGI-I is a 7-point scale used to rate the improvement of participants' condition at the time of assessment. Compared to the patient's condition at baseline, the participants' condition was rated as 1 = very much improved since initiation of treatment; 2 = much improved; 3 = minimally improved; 4 = no change from baseline; 5 = minimally worse; 6 = much worse; 7 = very much worse since the initiation of treatment. Higher scores indicate a worse outcome. The number of participants with minimally or better improvements (score of 3 or better) are being reported.
| Participants | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Number of Participants With Minimally or Better Clinical Global Impression of Improvement (CGI-I) Score at Week 12 | 17 | 12 | 15 |
| kilogram | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Mean Change From Baseline in Body Weight | -0.03 ± 3.09 | -0.14 ± 1.98 | 1.37 ± 1.28 |
| kg/m^2 | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Mean Change From Baseline in Body Mass Index (BMI) | 0 ± 0.98 | -0.04 ± 0.66 | 0.45 ± 0.45 |
| centimeters | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Mean Change From Baseline in Waist Circumference | 0.41 ± 5.36 | -0.53 ± 2.07 | 1.34 ± 3.13 |
| mmHg | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Diastolic blood pressure | 1.7 ± 6.19 | 0 ± 7.05 | -0.2 ± 5.71 |
| Systolic blood pressure | 0.3 ± 9.38 | 0 ± 8.41 | 0.3 ± 5.66 |
| beats/minute | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Mean Change From Baseline in Heart Rate | 1.0 ± 8.46 | -3.1 ± 9.13 | 0.1 ± 6.52 |
| breaths/minute | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Mean Change From Baseline in Respiratory Rate | -0.6 ± 2.13 | 0.1 ± 1.37 | 0 ± 1.45 |
| Celsius | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Mean Change From Baseline in Temperature | -0.07 ± 0.34 | 0.06 ± 0.20 | -0.02 ± 0.19 |
| Participants | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Supine systolic blood pressure, Day 85: <-20 | 0 | 0 | 0 |
| Supine systolic blood pressure, Day 85: >20 | 1 | 0 | 0 |
| Supine diastolic blood pressure, Day 85: <-10 | 0 | 1 | 0 |
| Supine diastolic blood pressure, Day 85: >10 | 2 | 1 | 0 |
| Heart rate, Day 85: <-20 | 0 | 0 | 0 |
| Heart rate, Day 85: >20 | 0 | 0 | 0 |
| Weight, Day 85: ≤-7% | 2 | 1 | 0 |
| Weight, Day 85: ≥7% | 1 | 0 | 0 |
| Participants | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| QTcF interval, Day 85: >450 msec | 0 | 1 | 0 |
| QTcF interval, Day 85: >480 msec | 0 | 0 | 0 |
| QTcF interval, Day 85: >500 msec | 0 | 0 | 0 |
The C-SSRS is a short questionnaire that is used to assess suicidal ideation (5 questions) and behavior (5 questions) since last patient visit. The questionnaire is completed by participants answering yes or no to each question.
| Participants | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|---|---|---|---|
| Screening, Suicidal ideation, Wish to be dead | 1 | 0 | 0 |
| Screening, Suicidal ideation, Non-specific active suicidal thoughts | 0 | 0 | 0 |
| Screening, Suicidal ideation, Active with any methods (not planned) without intent to act | 0 | 0 | 0 |
| Screening, Suicidal ideation, Active with some intent to act, without specific plan | 0 | 0 | 0 |
| Screening, Suicidal ideation, Active with specific plan and intent | 0 | 0 | 0 |
| Screening, Suicidal behavior, Preparatory acts or behavior | 0 | 0 | 0 |
| Screening, Suicidal behavior, Aborted attempt | 0 | 0 | 0 |
| Screening, Suicidal behavior, Interrupted attempt | 0 | 0 | 0 |
| Screening, Suicidal behavior, Actual attempt | 0 | 0 | 0 |
| Screening, Suicidal behavior, Completed suicide | 0 | 0 | 0 |
| Day 14, Suicidal ideation, Wish to be dead | 0 | 1 | 0 |
| Day 14, Suicidal ideation, Non-specific active suicidal thoughts | 0 | 0 | 0 |
| Day 14, Suicidal ideation, Active with any methods (not planned) without intent to act | 0 | 0 | 0 |
| Day 14, Suicidal ideation, Active with some intent to act, without specific plan | 0 | 0 | 0 |
| Day 14, Suicidal ideation, Active with specific plan and intent | 0 | 0 | 0 |
| Day 14, Suicidal behavior, Preparatory acts or behavior | 0 | 0 | 0 |
| Day 14, Suicidal behavior, Aborted attempt | 0 | 0 | 0 |
| Day 14, Suicidal behavior, Interrupted attempt | 0 | 0 | 0 |
| Day 14, Suicidal behavior, Actual attempt | 0 | 0 | 0 |
| Day 14, Suicidal behavior, Completed suicide | 0 | 0 | 0 |
| Day 29, Suicidal ideation, Wish to be dead | 1 | 1 | 0 |
| Day 29, Suicidal ideation, Non-specific active suicidal thoughts | 0 | 1 | 0 |
| Day 29, Suicidal ideation, Active with any methods (not planned) without intent to act | 0 | 1 | 0 |
| Day 29, Suicidal ideation, Active with some intent to act, without specific plan | 0 | 0 | 0 |
| Day 29, Suicidal ideation, Active with specific plan and intent | 0 | 0 | 0 |
| Day 29, Suicidal behavior, Preparatory acts or behavior | 0 | 0 | 0 |
| Day 29, Suicidal behavior, Aborted attempt | 0 | 0 | 0 |
| Day 29, Suicidal behavior, Interrupted attempt | 0 | 0 | 0 |
| Day 29, Suicidal behavior, Actual attempt | 0 | 0 | 0 |
| Day 29, Suicidal behavior, Completed suicide | 0 | 0 | 0 |
| Day 85, Suicidal ideation, Wish to be dead | 0 | 0 | 0 |
| Day 85, Suicidal ideation, Non-specific active suicidal thoughts | 0 | 0 | 0 |
| Day 85, Suicidal ideation, Active with any methods (not planned) without intent to act | 0 | 0 | 0 |
| Day 85, Suicidal ideation, Active with some intent to act, without specific plan | 0 | 0 | 0 |
| Day 85, Suicidal ideation, Active with specific plan and intent | 0 | 0 | 0 |
| Day 85, Suicidal behavior, Preparatory acts or behavior | 0 | 0 | 0 |
| Day 85, Suicidal behavior, Aborted attempt | 0 | 0 | 0 |
| Day 85, Suicidal behavior, Interrupted attempt | 0 | 0 | 0 |
| Day 85, Suicidal behavior, Actual attempt | 0 | 0 | 0 |
| Day 85, Suicidal behavior, Completed suicide | 0 | 0 | 0 |
Collected over All adverse events (AEs) were collected from baseline up to end of study, approximately 1 year 8 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P 300 mg | 0/27 (0%) | 2/27 (7.4%) | 3/27 (11.1%) |
| GWP42003-P 1000 mg | 0/24 (0%) | 2/24 (8.3%) | 3/24 (12.5%) |
| Pooled Placebo (Treatment Period) | 0/26 (0%) | 1/26 (3.8%) | 3/26 (11.5%) |
| Pooled Placebo (Placebo Run-In Period) | 0/95 (0%) | 0/95 (0%) | 0/95 (0%) |
| Event | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo (Treatment Period) | Pooled Placebo (Placebo Run-In Period) |
|---|---|---|---|---|
| COVID-19Infections and infestations | 2/27 | 0/24 | 0/26 | — |
| Coronavirus infectionInfections and infestations | 0/27 | 1/24 | 0/26 | — |
| UrticariaSkin and subcutaneous tissue disorders | 0/27 | 1/24 | 0/26 | — |
| HospitalizationSurgical and medical procedures | 0/27 | 0/24 | 1/26 | — |
| Event | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo (Treatment Period) | Pooled Placebo (Placebo Run-In Period) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/27 | 3/24 | 3/26 | 0/95 |
| COVID-19Infections and infestations | 2/27 | 0/24 | 0/26 | 0/95 |
Demographics and baseline characteristics were assessed in the Full Analysis Set in the Treatment Period.
| Age, Categorical(Participants) | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 27 | 24 | 26 | 77 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo | Total |
|---|---|---|---|---|
| Mean | 37.5 ± 7.53 | 39.2 ± 8.21 | 38.7 ± 8.87 | 38.4 ± 8.13 |
| Sex: Female, Male(Participants) | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo | Total |
|---|---|---|---|---|
| Female | 6 | 7 | 7 | 20 |
| Male | 21 | 17 | 19 | 57 |
| Race (NIH/OMB)(Participants) | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 11 | 7 | 10 | 28 |
| White | 15 | 17 | 14 | 46 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo | Total |
|---|---|---|---|---|
| United States | 20 | 14 | 18 | 52 |
| Poland | 1 | 1 | 1 | 3 |
| Serbia | 6 | 8 | 6 | 20 |
| Spain | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Mar 2022, 18 months.
Results were first posted in Jun 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol